Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Bio-Techne

TECH Healthcare Unknown Updated July 31, 2026
$72.09
52W $43.20 – $72.37
60/100
$11.29B
101.5
1.29
AI Committee Verdict
Watch
Conviction: Contested · 67% agreement · 6 analysts
-21.5%
Contested

Is TECH Bullish or Bearish?

Mixed. Innellis AI committee rates Bio-Techne (TECH) Watch with a composite score of 60/100 , based on 6 analysts with 67% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +0.33 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -19.67 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
  • RSI at 73 is in overbought territory — Technical
  • MACD histogram negative -- bearish momentum — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
  • Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
  • Weekly RSI at 76 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
60/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 12%
of 93 Healthcare peers
Growth Analyst bullish
85 / 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
43 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened from 53.4 to 59.7.

Analyst-level changes:
  • Growth Analyst: stance neutral->bullish; score 48->85 (+37).
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst: score 75->70 (-5).
  • Value Analyst abstained (was bearish at 40).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
74.3
Overbought
MACD Histogram
-0.625
Bearish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Lh Ll
Bollinger %B
0.81
Inside Bands
Price vs Moving Averages
EMA 9
$71.83 Above
EMA 21
$70.19 Above
EMA 50
$65.04 Above
EMA 200
$59.10 Above

Fundamental Analysis

Valuation
47
Growth
58
Profitability
0
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 101.5×
P/B Ratio 5.39×
PEG Ratio -7.02
Dividend Yield 0.00%
52W High $72.37
52W Low $43.20
Quality & Growth
ROE 3.8%
ROA 2.9%
Gross Margin 65.0%
Operating Margin 12.7%
Revenue Growth YoY
Debt / Equity 0.14
AI Fundamental Assessment
P/E ratio of 101.5 (rich relative to a 15-40x range); Price-to-book of 5.4x; PEG ratio of -7.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.0%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.6%; Current ratio of 4.49 (healthy short-term liquidity); Debt-to-equity of 0.14; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (1.73); Most recent quarter missed estimates by 3.3%; EPS growth accelerating (+9.5% -> +15.2% QoQ); Analyst estimates rising over recent quarters
Get the Full TECH Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore TECH Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime